uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centre for Research and Development, Gävleborg. Gävle Cent Hosp, Dept Surg, Gävle, Sweden; Umeå Univ, Urol & Androl Unit, Dept Surg & Perioperat Sci, Umeå, Sweden.ORCID iD: 0000-0003-1160-3790
Show others and affiliations
2012 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 130, no 1, p. 129-137Article in journal (Refereed) Published
Abstract [en]

The aim of this study was to investigate if a genetic risk score including 33 common genetic variants improves prediction of prostate cancer when added to measures of prostate‐specific antigen (PSA). We conducted a case–control study nested within the Northern Sweden Health and Disease Cohort (NSHDC), a prospective cohort in northern Sweden. A total of 520 cases and 988 controls matched for age, and date of blood draw were identified by linkage between the regional cancer register and the NSHDC. Receiver operating characteristic curves with area under curve (AUC) estimates were used as measures of prostate cancer prediction. The AUC for the genetic risk score was 64.3% [95% confidence interval (CI) = 61.4–67.2], and the AUC for total PSA and the ratio of free to total PSA was 86.2% (95% CI = 84.4–88.1). A model including the genetic risk score, total PSA and the ratio of free to total PSA increased the AUC to 87.2% (95% CI = 85.4–89.0, p difference = 0.002). The addition of a genetic risk score to PSA resulted in a marginal improvement in prostate cancer prediction that would not seem useful for clinical risk assessment.

Place, publisher, year, edition, pages
2012. Vol. 130, no 1, p. 129-137
Keywords [en]
early detection, prostate cancer, prostate-specific antigen, single-nucleotide polymorphism
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-253317DOI: 10.1002/ijc.25986ISI: 000297851300014PubMedID: 21328341OAI: oai:DiVA.org:uu-253317DiVA, id: diva2:814134
Funder
Västerbotten County CouncilSwedish Cancer SocietySwedish Research CouncilAvailable from: 2015-05-26 Created: 2015-05-26 Last updated: 2018-07-13Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Holmström, Benny

Search in DiVA

By author/editor
Holmström, Benny
By organisation
Centre for Research and Development, Gävleborg
In the same journal
International Journal of Cancer
Urology and NephrologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 357 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf